Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Summit Therapeutics Inc SMMT

Healthcare Biotechnology
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF... see more

Recent & Breaking News (NDAQ:SMMT)

Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019

GlobeNewswire June 20, 2019

Increased BARDA Award and Option Exercise

GlobeNewswire June 18, 2019

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019

GlobeNewswire June 12, 2019

Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

PR Newswire June 7, 2019

Notice of First Quarter Results

GlobeNewswire June 5, 2019

Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019

GlobeNewswire April 14, 2019

Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

PR Newswire April 12, 2019

Antimicrobials Working Group Announces Updates to Leadership Team

PR Newswire January 17, 2019

Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week

GlobeNewswire November 12, 2018

Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference

GlobeNewswire November 7, 2018

Summit Recognises C. difficile Awareness Month

GlobeNewswire November 1, 2018

New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire October 17, 2018

Summit Therapeutics to Participate in Upcoming Investor Events

GlobeNewswire October 10, 2018

Surrender of Share Options

GlobeNewswire October 7, 2018

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018

PR Newswire October 3, 2018

Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018

GlobeNewswire October 3, 2018

Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018

GlobeNewswire September 26, 2018

Summit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational Progress

GlobeNewswire September 20, 2018

Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018

GlobeNewswire September 14, 2018

Summit Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 14, 2018